Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J ZARAFONETIS

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Research Communications in Chemical Pathology and Pharmacology|June 1, 1978
Metabolism of para-aminobenzoate over timeG S Duboff, C J Zarafonetis
Research Communications in Chemical Pathology and Pharmacology|February 1, 1979
Para-aminobenzoate inhibition of precipitation of urine saltsC J Zarafonetis, J G Batsakis, R A Wolfe
The Annals of Thoracic Surgery|August 1, 1976
Gastroesophageal reflux in esophageal scleroderma: diagnosis and implicationsM B Orringer, L Dabich, C J Zarafonetis, et al.
Surgery|October 1, 1981
Combined Collis gastroplasty--fundoplication operations for scleroderma reflux esophagitisM B Orringer, J S Orringer, L Dabich, et al.
Journal of the American Academy of Dermatology|July 1, 1986
Potassium para-aminobenzoate and liver function test findingsC J Zarafonetis, L Dabich, E B DeVol, et al.
Journal of Clinical Epidemiology|January 1, 1988
Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survivalC J Zarafonetis, L Dabich, D Negri, et al.
Respiration; International Review of Thoracic Diseases|January 1, 1989
Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacityC J Zarafonetis, L Dabich, E B Devol, et al.
Clinical and Experimental Rheumatology|July 1, 1988
Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapyC J Zarafonetis, L Dabich, J J Skovronski, et al.
Clinical Pharmacology and Therapeutics|August 1, 1978
Clinically significant adverse effects in a Phase 1 testing programC J Zarafonetis, P A Riley, P W Willis, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Research Communications in Chemical Pathology and Pharmacology|June 1, 1978
Metabolism of para-aminobenzoate over timeG S Duboff, C J Zarafonetis
Research Communications in Chemical Pathology and Pharmacology|February 1, 1979
Para-aminobenzoate inhibition of precipitation of urine saltsC J Zarafonetis, J G Batsakis, R A Wolfe
The Annals of Thoracic Surgery|August 1, 1976
Gastroesophageal reflux in esophageal scleroderma: diagnosis and implicationsM B Orringer, L Dabich, C J Zarafonetis, et al.
Surgery|October 1, 1981
Combined Collis gastroplasty--fundoplication operations for scleroderma reflux esophagitisM B Orringer, J S Orringer, L Dabich, et al.
Journal of the American Academy of Dermatology|July 1, 1986
Potassium para-aminobenzoate and liver function test findingsC J Zarafonetis, L Dabich, E B DeVol, et al.
Journal of Clinical Epidemiology|January 1, 1988
Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survivalC J Zarafonetis, L Dabich, D Negri, et al.
Respiration; International Review of Thoracic Diseases|January 1, 1989
Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacityC J Zarafonetis, L Dabich, E B Devol, et al.
Clinical and Experimental Rheumatology|July 1, 1988
Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapyC J Zarafonetis, L Dabich, J J Skovronski, et al.
Clinical Pharmacology and Therapeutics|August 1, 1978
Clinically significant adverse effects in a Phase 1 testing programC J Zarafonetis, P A Riley, P W Willis, et al.
Pageof 1